Michael Butler, MD
Interventional Cardiology · Huntsville, ALNPI 1306058557
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 80.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $33,800 and has fallen 71.3% since, to $9,697 in 2025. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $171.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$87K
- Amgen$8K
- Abbott$4K
- Novartis$2K
- Boston Scientific$1K
- Pfizer$810
- plus $5K from 30 others
Across 134 payments — averaging $6047.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Circulation Inc$760K
- Abbott$20K
- Shockwave Medical, Inc$20K
- Medtronic$9K
What the payments were for
- Consulting fees$64,80060%
- Speaking & faculty fees$14,87614%
- Travel & lodging$10,68810%
- Food & beverage$18,23217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 120 | $87,469 |
| Amgen | 48 | $8,065 |
| Abbott | 64 | $3,841 |
| Novartis | 96 | $1,738 |
| Boston Scientific | 27 | $1,393 |
| Pfizer | 44 | $810 |
| Johnson & Johnson | 50 | $775 |
| Medtronic(2 entities) | 18 | $671 |
| Boehringer Ingelheim | 24 | $545 |
| E.r. Squibb & Sons, L.L.C. | 25 | $511 |
| Abiomed | 4 | $397 |
| Regeneron Healthcare Solutions, Inc. | 13 | $308 |
| Bayer | 11 | $238 |
| Sanofi-aventis U.S. LLC | 12 | $216 |
| Esperion Therapeutics, Inc. | 11 | $204 |
| Novo Nordisk | 9 | $174 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $172 |
| Merck | 8 | $154 |
| Cardiovascular Systems Inc. | 9 | $139 |
| AstraZeneca | 8 | $136 |
| Asahi Intecc USA, Inc. | 1 | $125 |
| EKOS Corporation | 1 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| W. L. Gore & Associates, Inc. | 1 | $45 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Siemens Medical Solutions USA, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| United Therapeutics Corporation | 1 | $28 |
| GE HealthCare | 2 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Endotronix, Inc. | 1 | $17 |
| Recor Medical Inc | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$69,268
- Repatha$7,358
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,995
- TRICLIP$1,352
- EVOQUE$401
- Optis Coronary Imaging System$387
- Impella$382
- NAVITOR$368
- SAPIEN 3 Ultra RESILIA$297
- WATCHMAN Access System$281
- AVVIGO Guidance System$265
- MitraClip System$250
- CoreValve Evolut$196
- COREVALVE EVOLUT R$148
- PASCAL$142
- WATCHMAN FLX$134
- ASAHI PTCA Guide Wire$125
- CAMZYOS$125
- OPTIS$114
- Watchman$111
How this compares
$108,596 in reported general payments places this provider in the 95th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 561 | $627,247 |
| JardianceEmpagliflozin | 383 | $441,059 |
| EntrestoSacubitril/Valsartan | 271 | $387,093 |
| Repatha SureclickEvolocumab | 247 | $208,517 |
| FarxigaDapagliflozin Propanediol | 115 | $116,305 |
| XareltoRivaroxaban | 67 | $82,643 |
| Praluent PenAlirocumab | 102 | $76,083 |
| MultaqDronedarone Hcl | 24 | $32,506 |
| BrilintaTicagrelor | 28 | $20,509 |
| MounjaroTirzepatide | 14 | $14,082 |
| Ranolazine ErRanolazine | 104 | $10,126 |
| NexletolBempedoic Acid | 11 | $9,647 |
| Metoprolol Succinate | 614 | $9,604 |
| VascepaIcosapent Ethyl | 16 | $9,238 |
| Atorvastatin Calcium | 750 | $9,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $810 | $627,247561 claims |
| Boehringer IngelheimJardiance, Pradaxa | $545 | $444,806394 claims |
| NovartisEntresto | $1,738 | $387,093271 claims |
| AstraZenecaFarxiga, Brilinta | $136 | $136,814143 claims |
| Johnson & JohnsonXarelto | $775 | $82,64367 claims |
| Sanofi-aventis U.S. LLCMultaq | $216 | $32,50624 claims |
| Esperion Therapeutics, Inc.Nexletol | $204 | $9,64711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Pochana ReddyHuntsville$100K
- Alejandro VasquezHuntsville$45K
- David DrenningHuntsville$31K
- Clarence GillHuntsville$13K
- Victor OkunrintemiHuntsville$12K
- Henry ChenHuntsville$8K
- Mihir KanitkarHuntsville$7K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.